More breakthroughs are on the horizon, as OCRA has awarded grants to 22 dedicated scientists at 15 prestigious medical institutions to enable future ovarian cancer discoveries. With this funding, OCRA … Continued
A randomized trial recently showed that patients with an ovarian cancer recurrence who undergo cytoreductive surgery along with chemotherapy show better survival rates than those who only receive chemotherapy. More than 400 … Continued
Dr. Anne van Harten, of the Sidney Kimmel Cancer Center at Thomas Jefferson University in Philadelphia, is a 2021 recipient of OCRA’s Ann and Sol Schreiber Mentored Investigator Award. With … Continued
OCRA grantees Ignacio Vázquez-García, PhD and Sohrab Shah, PhD, of Memorial Sloan Kettering Cancer Center, along with colleagues, have found that distinct mutational processes determine the different mechanisms by which certain ovarian cancer … Continued
Dr. Sammy Ferri-Borgogno, of UT MD Anderson Cancer Center, is a 2021 recipient of OCRA’s Ann and Sol Schreiber Mentored Investigator Award. With her project, “Spatially-Resolved Cellular and Transcriptome Analyses … Continued
Dr. Arun Kanakkanthara, of Mayo Clinic, is a 2021 recipient of OCRA’s Liz Tilberis Early Career Award. With his project, “Exploiting a Metabolic Dependency of PARPinhibitor-Resistant Ovarian Cancer,” Dr. Kanakkanthara … Continued
Dr. Wei Zhou, of The Wistar Institute in Philadelphia, is a 2021 recipient of OCRA’s Ann & Sol Schreiber Mentored Investigator Award, mentored by Dr. Rugang Zhang. With his project, … Continued
We’re pleased to report that thanks to your support, OCRA grantees made breathtaking strides toward better understanding, preventing and treating ovarian cancer this year. Read about our OCRA Grantees’ discoveries in 2020 → The … Continued
This time of year always has us reflecting on what we’ve accomplished, what we hope to achieve in the future, and how we — with the support of the entire ovarian cancer … Continued
An interdisciplinary group of researchers from around the country analyzed tumor samples from nearly 10,000 patients with 34 types of cancer to reveal unique genetic switches associated with each tumor … Continued
Dr. Liya Ding, of Dana-Farber Cancer Institute, is a 2021 recipient of OCRA’s Liz Tilberis Early Career Award. With her project, “Targeting Therapeutic Resistance to PARP Inhibition in Ovarian Cancer,” … Continued
In what could prove to be a game-changer for ovarian cancer debulking procedures, the U.S. Food and Drug Administration (FDA) has approved Cytalux (pafolacianine), an imaging drug designed to help … Continued
Get email updates about research news, action alerts, and ways to join the fight.
